Log in

Relevant bibliographies by topics / Ribavirine / Journal articles

To see the other types of publications on this topic, follow the link: Ribavirine.

Journal articles on the topic 'Ribavirine'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ribavirine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ciancio, Alessia. "Sofosbuvir: an all-around drug in hepatitis C treatment new era – The first phase." Reviews in Health Care 6, no. 2 (April 30, 2015): 41–52. http://dx.doi.org/10.7175/rhc.v6i2.1164.

Full text

Abstract:

Chronic hepatitis C virus (HCV) infection is a slowly progressive disease affecting more than 185 million people worldwide. For many years, the combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV) has been the backbone of treatment for patients infected with HCV. More than two years ago, the first generation direct-acting antiviral agents (DAAs) – the protease inhibitors boceprevir and telaprevir – were approved for treatment of genotype 1 patients, doubling the cure rate. The new DAAs that have been developed, are effective for multiple genotypes, improve rates of sustained viral response with fewer side effects, simplify dosing and drug-drug interactions, and in some patients, offer the promise of interferon-free and/or ribavirin-free therapy. These new agents include the recently approved second generation protease inhibitor, the HCV NS5B polymerase inhibitor sofosbuvir and the NS3/4A protease inhibitor simeprevir as well as several other agents that are currently in later phases of development. With sofosbuvir-based regimens, successful interferon-free treatment is now available across all genotypes. In fact sofosbuvir is very effective in combination with Peg-interferon and ribavirine or with ribavirine alone or with other direct anti-viral agents. The following assessment evaluates the evidence on the clinical effectiveness and harms of sofosbuvir for the treatment of chronic hepatitis C.

APA, Harvard, Vancouver, ISO, and other styles

2

Hubert, P. "Ribavirine et ventilation mécanique." Archives de Pédiatrie 3, no. 2 (February 1996): 186. http://dx.doi.org/10.1016/0929-693x(96)85076-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zivkovic, Milovan, Zoran Todorovic, Predrag Canovic, and Zeljko Mijanovic. "Application of ribavirin in patients having hemorrhagic fever with renal syndrome." Medical review 62, no. 1-2 (2009): 63–67. http://dx.doi.org/10.2298/mpns0902063z.

Full text

Abstract:

Introduction. Hemorrhagic fever with renal syndrome (HFRS) is an acute infective disease of a zoonose type characterized by an abrupt beginning, prominent hemorrhagic syndrome as well as symptoms and signs of acute renal insufficiency. The clinical picture of this disease, which is leading in terms of its natural principal seat in the region of Northern-east Montenegro, ranges from non-apparent to very severe forms and mortality it causes is about 10%.Up to date, no efficient etio-trophic means has been discovered. Several studies suggest that an early use of anti virus medicament Ribavirine leads to decrease of mortality rate. The main aim of this study is to present our results achieved in an attempt to apply this medicament in treating HFRS. Material and methods. In total, we have treated 58 patients with symptoms and signs of HGSBS. Five of them, who were admitted to the Department in the first three days were treated by Ribavirine orally in doses of 2x400 mg. Compared to patients who were not treated by Ribavirine, a faster decrease of thrombocytes was noticed in them, which required the discontinuation of the medicament treatment. Thereafter, thrombocytes started to increase and their normalization followed faster than in patients who were not treated by this medicament. The above patients developed a moderately severe clinical picture of the disease, and middle maximum values of urea and creatinine were lower in patients who were not treated by the medicament. No patient developed a severe form of the disease and there were neither dialyzed nor died ones. The mortality rate in patients who were not treated by the medicament was 3.44% and the percent of the dialyzed was 5.17%. Results. Application of Ribavirine at the very beginning of HFRS is considered to be with a very good reason in combination with obligatory follow up of clinical and laboratory parameters and particularly of thrombocyte values, the decrease of which can lead to spontaneous bleedings. Because of the small number of patients to whom we gave this medicament it is difficult to come to a conclusion on the extent of its affect on the clinical picture in our patients.

APA, Harvard, Vancouver, ISO, and other styles

4

M., J. M. "La ribavirine, traitement efficace de l’hépatite E." Revue Francophone des Laboratoires 2014, no. 465 (September 2014): 21. http://dx.doi.org/10.1016/s1773-035x(14)72619-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sizun, J. "Virus respiratoire syncytial, immunoglobulines spécifiques et ribavirine." Archives de Pédiatrie 4, no. 6 (June 1997): 554. http://dx.doi.org/10.1016/s0929-693x(97)87579-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ventura, F., JJ Cheseaux, J. Cotting, and JP Guignard. "Infections à virus respiratoire syncytial et ribavirine." Archives de Pédiatrie 5, no. 7 (July 1998): 809. http://dx.doi.org/10.1016/s0929-693x(98)80072-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Saadoun, D., D. Sene, B. Terrier, L. Perard, F. Blanc, P. Ghillani, Z. Amoura, and P. Cacoub. "Rituximab et Peg-IFN A/ribavirine comparé au Peg-IFN A/ribavirine dans les vascularites cryoglobulinémiques associées au VHC." La Revue de Médecine Interne 30 (December 2009): S351—S352. http://dx.doi.org/10.1016/j.revmed.2009.10.078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Karaaslan, H., V. Loustaud-Ratti, P. Soria, E. Liozon, V. Allot, Y. Le Meur, S. Rogez, F. Paraf, F. Labrousse, and E. Vidal. "Traitement des glomérulonéphrites membranoprolifératives liées au virus C par la bithérapie interféron alpha-ribavirine : maintenir la ribavirine même à doses réduites !" La Revue de Médecine Interne 22 (June 2001): 166. http://dx.doi.org/10.1016/s0248-8663(01)83623-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

CENGİZ, A. Tevfik, Lügen CENGİZ, Mehmet KIYAN, Muzaffer GÖZ, G. İştar DOLAPÇI, and Meltem TIBET. "Prevention and Treatment of AIDS-IV." European Journal of Therapeutics 3, no. 1 (January 1, 1992): 101–13. http://dx.doi.org/10.58600/eurjther.19920301-1267.

Full text

Abstract:

In this article principles of prevention and treatınent was explained for AIDS which has been an important and current health problem. At the same time, the other side of this subject, the importance of AIDS both for mother and infant is emphasized the behavior male and female patients with AIDS was dwelled on and activity of antiviral agents like AZT,ddc,ddı,suramine, interferon and ribavirine, was reviewed.

APA, Harvard, Vancouver, ISO, and other styles

10

Rinehart, Jason, and Lisa Stottlemyer. "La neuropathie optique ischémique antérieure bilatérale durant le traitement à l’interféron et à la ribavirine." Canadian Journal of Optometry 78, no. 1 (March 31, 2016): 27. http://dx.doi.org/10.15353/cjo.78.479.

Full text

Abstract:

Le virus de l’hépatite C (HC) est un agent pathogène à transmission hématogène qui cause souvent une infection chronique du foie et expose les patients à la cirrhose, à la décompensation hépatique et au carcinome hépatocellulaire. Le traitement vise à faire disparaître le virus afin de réduire au minimum la morbidité et la mortalité causées par l’hépatite C. Comme traitement traditionnel, on utilise une combinaison interféron pégylé (IFN) et ribavirine qui cause souvent des effets secondaires à la fois systémiques et oculaires. Les hémorragies rétiniennes et les nodules cotonneux constituent les effets secondaires oculaires les plus courants, même si l’on a attribué, dans de rares cas, des événements indésirables ophtalmiques plus importants au traitement à l’IFN. Nous discutons ici d’un cas de neuropathie optique ischémique antérieure (NOIA) bilatérale qui s’est produit au cours d’un traitement à l’IFN et à la ribavirine contre l’hépatite C de génotype 1. Nous passons en revue la pathogénèse proposée des effets secondaires oculaires de ce traitement, ainsi que la pathogénèse et les facteurs de risque associés à la NOIA même. Enfin, nous formulerons des recommandations cliniques portant sur le dépistage d’autres problèmes en sus de la rétinopathie si un patient se présente avec des complications ophtalmiques.

APA, Harvard, Vancouver, ISO, and other styles

11

Rojas-Estapé, M., C. Iglesias Rodriguez, and L. Garcia Murillo. "Hospitalized psychoses after liver transplantation." European Psychiatry 26, S2 (March 2011): 395. http://dx.doi.org/10.1016/s0924-9338(11)72103-4.

Full text

Abstract:

Calcineurin inhibitors can cause neurological and psychiatric side effects. Mild symptoms to severe complications can be found.Case presentationWe report a 49 year old man who received an orthotopic liver transplantation in May 2010. He received tacrolimus. Ten days later, while he was still in Hospital, he suffered behavioural disorders, being psychotic with delusions of persecution; he called the police thinking that he was being poisened by the staff of the Hospital. Although his Tacrolimus blood concentration had been kept in the normal range, his symptoms improved dramatically when the Tacrolimus was changed into Cyclosporine and Haloperidol was introduced at high doses (7 mg/day) for 10 days when the dose was reduced to 4 mg/day.Medical historyChronic hepatitis VHC 1a in 1994. Received treatment with Interferon alfa in 1997 with no antiviral answer. In 2001 new treatment with pegylated Interferon and Ribavirine with positive virological answer but had to be stopped because of psychoses secondary to treatment. New treatment in March 2006 to March 2007 with Pegasys+Ribavirine with rapid virologycal answer with prophylactic Olanzapine 5 mg during a year with no psychotic symptons. In May 2009, Child Pugh C10, in list for liver transplantation.We discuss the implications of these findings and the relevance for future clinical care in these patients.

APA, Harvard, Vancouver, ISO, and other styles

12

Solas, Caroline, Maxime Paré, Sylvie Quaranta, and Françoise Stanke-Labesque. "Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine." Therapies 66, no. 3 (May 2011): 221–30. http://dx.doi.org/10.2515/therapie/2011036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Aujard, Y. "Infections à virus respiratoire syncytial et ribavirine : La controverse continue." Archives de Pédiatrie 5, no. 2 (February 1998): 107–10. http://dx.doi.org/10.1016/s0929-693x(97)86822-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Odièvre, M., A. Gros-Desormeaux, S. Jouannault, and M. Tison. "Céphalées : un risque méconnu de la ribavirine chez le nourrisson?" Archives de Pédiatrie 5, no. 3 (March 1998): 347. http://dx.doi.org/10.1016/s0929-693x(97)89389-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Chudinov, Mikhail V., Andrey V. Matveev, Alexander N. Prutkov, Irina D. Konstantinova, Ilja V. Fateev, Vladimir S. Prasolov, Olga A. Smirnova, Alexander V. Ivanov, Georgy A. Galegov, and Petr G. Deryabin. "Novel 5-alkyl(aryl)-substituted ribavirine analogues: synthesis and antiviral evaluation." Mendeleev Communications 26, no. 3 (May 2016): 214–16. http://dx.doi.org/10.1016/j.mencom.2016.04.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Durand, JM, P. Cacoub, F. Lunel-Fabiani, E. Cretel, G. Kaplanski, J. Cosserat, O. Blétry, C. Frances, J. Soubeyrand, and P. Godeau. "Traitement des cryoglobulinémies liée au virus de l'hépatite C par la ribavirine." La Revue de Médecine Interne 18 (May 1997): s83. http://dx.doi.org/10.1016/s0248-8663(97)80293-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Crochet, M., I. Ingster-Moati, G. Even, and P. Dupuy. "Rétinopathie à l’interféron-α associé à la ribavirine : atteinte de l’électro-oculogramme." Journal Français d'Ophtalmologie 27, no. 3 (March 2004): 257–62. http://dx.doi.org/10.1016/s0181-5512(04)96127-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Launay, M., P. Borentain, G. Kownacki, A. Verine, F. Rouby, C. Solas, D. Botta-Fridlund, and S. Gensollen. "Aplasie médullaire chez un patient VHC greffé hépatique traité par sofosbuvir+ribavirine." Le Pharmacien Hospitalier et Clinicien 49, no. 2 (June 2014): e113-e114. http://dx.doi.org/10.1016/j.phclin.2014.04.241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Gambier, N., U. Warzocha, R. Dhôte, and D. Roulot. "Traitement par Ribavirine d’une cirrhose virale E chez un patient non immunodéprimé." La Revue de Médecine Interne 31 (December 2010): S474—S475. http://dx.doi.org/10.1016/j.revmed.2010.10.291.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Pijak, Michal R., and Veronika Csibova. "354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy." World Allergy Organization Journal 5 (February 2012): S113—S114. http://dx.doi.org/10.1097/01.wox.0000412117.18651.08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

CHOSSEGROS, P. "In kidney graft recipients ribavirine is able to reduce HCV viral load." Hepatology 22, no. 4 (October 1995): A403. http://dx.doi.org/10.1016/0270-9139(95)95334-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Pol, S., F. Carrat, F. Bani-Sadr, E. Rosenthal, F. Lunel, P. Morand, D. Salmon, G. Pialoux, P. Cacoub, and C. Perronne. "C09 - Résultats finaux de ribavic (ANRS Hc02) : étude contrôlée randomisée de l’interferon pégylé alfa-2b plus ribavirine vs interferon alfa-2b plus ribavirine chez les co-infectés VIH/VHC." Gastroentérologie Clinique et Biologique 28, no. 8-9 (August 2004): 766. http://dx.doi.org/10.1016/s0399-8320(04)95071-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Sergio, Neri, Travali Salvatore, Bertino Gaetano, Pulvirenti Davide, Italiano Claudio, Libbra Massimo, Mauceri Barbara, et al. "Immune response in addicts with chronic hepatitis C treated with interferon and ribavirine." Journal of Gastroenterology and Hepatology 22, no. 1 (January 2007): 74–79. http://dx.doi.org/10.1111/j.1440-1746.2006.04423.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Dhôte, R., K. Lacut, T. Thevenot, C. Bachmeyer, and B. Christoforov. "Traitement par ribavirine et interféron d'une cryoglobulinémie au cours d'une hépatite chronique C." La Revue de Médecine Interne 18 (May 1997): s158. http://dx.doi.org/10.1016/s0248-8663(97)80411-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Melki, Marianne, Francois Gallet, Marc Bourliere, Isabelle Bartolomei-Portal, Francois Blanc, Pierre Blanc, Pascal Perney, et al. "Resistance of HCV genotype 4 to interferon (IFN) alone or to interferon-ribavirine." Gastroenterology 118, no. 4 (April 2000): A1468. http://dx.doi.org/10.1016/s0016-5085(00)81775-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Khalil, Ali, Florent Gonzalez, Elias El Riachy, Damien Lucidarme, and Bernard Filoche. "Panophtalmie au cours du traitement d’une hépatite C par interferon pégylé et ribavirine." Gastroentérologie Clinique et Biologique 29, no. 11 (November 2005): 1187–88. http://dx.doi.org/10.1016/s0399-8320(05)82192-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Loustaud-Ratti, V., E. Liozon, S. Alain, H. Bezanahary, S. Roubertou, L. Magy, C. Bonnet, P. Soria, and E. Vidal. "Neuropathie périphérique motrice, cryoglobulinémie,et virus C: Une patiente miraculée par la ribavirine." La Revue de Médecine Interne 24 (June 2003): 94s. http://dx.doi.org/10.1016/s0248-8663(03)80199-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Cottin, J. F., A. Sardet, C. Grosskopf, and G. Tournier. "Traitement par aérosol de ribavirine des infections à virus respiratoire syncytial du nourrisson." Médecine et Maladies Infectieuses 23 (November 1993): 892. http://dx.doi.org/10.1016/s0399-077x(05)80375-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Menard, A., C. Solas, P. Colson, S. Benhaim, V. Pradel, F. Vion-Dury, and I. Poizot-Martin. "M-01 Concentration plasmatique résiduelle de ribavirine (CRBV) et charge virale VHC (CV-VHC) à S4 sous bithérapie PegInterferon alpha- ribavirine (PEGIFN/RBV) chez les patients co-infectés VIH-VHC." Médecine et Maladies Infectieuses 38 (June 2008): S167. http://dx.doi.org/10.1016/s0399-077x(08)73174-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Pawłowska, M., and W. Halota. "Immunological evaluation of ribavirine and interferon-alpha therapy in patients with chronic hepatitis C." Journal of Hepatology 32 (2000): 96. http://dx.doi.org/10.1016/s0168-8278(00)80701-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bonaventure, C., V. Calay, M. Chevallier, P. H. Merle, P. Pradat, and C. Trepo. "CA17 - Bénéfice du traitement d’entretien par monothérapie ribavirine au cours des hépatites chroniques C." Gastroentérologie Clinique et Biologique 28, no. 8-9 (August 2004): 786. http://dx.doi.org/10.1016/s0399-8320(04)95111-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Belkahla, N., H. Kchir, N. Maamouri, H. Ouerghi, F. B. Hariz, S. Chouaib, H. Chaabouni, and N. B. Mami. "Réactivation d’une tuberculose sous bithérapie interféron-pégylé et ribavirine pour une hépatite chronique C." La Revue de Médecine Interne 31, no. 11 (November 2010): e1-e3. http://dx.doi.org/10.1016/j.revmed.2009.11.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Marcellin, P., V. Canva, K. Barange, Y. Benhamou, P. Couzigou, D. Larrey, C. Trépo, C. Hézode, D. Botta-Fridlund, and D. Jensen. "CA 65-Efficacité d’une dose standard et d’une dose d’induction de PEG interféron alpha-2a (40KD) plus ribavirine chez des malades non répondeurs au peginterféron alpha 2b/ribavirine : analyse intermédiaire de l’étude repeat." Gastroentérologie Clinique et Biologique 30, no. 8-9 (August 2006): 1081. http://dx.doi.org/10.1016/s0399-8320(06)73475-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Hézode, C., M. Bouvier-Alias, C. Costentin, F. Medkour, E. Franc-Poole, M. Aalyson, J. Alam, A. Mallat, D. Dhumeaux, and J. M. Pawlotsky. "CA 68-Effet de l’inhibition de l’impdh par le merimepodib (MMPD), administré seul ou en combinaison avec la ribavirine (RBV), sur la réplication du VHC : implications pour le mécanisme d’action de la ribavirine." Gastroentérologie Clinique et Biologique 30, no. 8-9 (August 2006): 1083. http://dx.doi.org/10.1016/s0399-8320(06)73478-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Blanche, P., D. Bouscary, T. B. N'Guyen, N. Galezowski, G. Herreman, and D. Sicard. "Traitement par la ribavirine d'une cryoglobulinémie et d'une thrombopénie liées au virus de l'hépatite C." La Revue de Médecine Interne 17 (January 1996): 471s. http://dx.doi.org/10.1016/s0248-8663(97)81091-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Khalil, Ali, Damien Lucidarme, Philippe Desurmont, Rima Hamdan-Khalil, and Bernard Filoche. "Maladie de Crohn au cours du traitement de l’hépatite chronique C par interféron et ribavirine." Gastroentérologie Clinique et Biologique 29, no. 2 (March 2005): 193–96. http://dx.doi.org/10.1016/s0399-8320(05)80736-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Pawłowska, M., W. Halota, and E. Topczewska-Staubach. "Influence of IFN and ribavirine on ICAM-1 serum concentration in chronic C hepatitis treatment." Journal of Hepatology 28 (1998): 200. http://dx.doi.org/10.1016/s0168-8278(98)80979-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Pons, B., A. Abergel, M. Ruivard, V. Rieu, A. C. Fouilhoux, and P. Philippe. "Sclérodermie généralisée au cours d'une hépatite chronique C traitée par interféron pégylé alpha et ribavirine." La Revue de Médecine Interne 23 (December 2002): 688s. http://dx.doi.org/10.1016/s0248-8663(02)80670-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Pialoux, G. "Efficacité de l’interféron pégylé associé à la ribavirine en cas de co-infection VIH-VHC." La Presse Médicale 34, no. 20 (November 2005): 1589–91. http://dx.doi.org/10.1016/s0755-4982(05)84230-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Lévêque, L., P. Bielefeld, C. Sgro, P. Hillon, T. Gabreau, B. Champigneulle, H. Makki, and J. F. Besancenot. "Sarcoïdose au cours du traitement de l'hépatite C par interféron alpha et ribavirine : deux cas." La Revue de Médecine Interne 21 (December 2000): 563. http://dx.doi.org/10.1016/s0248-8663(00)90195-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Lévêque, L., A. de Boulard, P. Bielefeld, C. Sgro, P. Hillon, T. Gabreau, B. Champigneulle, H. Makki, and J. F. Besancenot. "Sarcoïdose au cours du traitement de l’hépatite C par interféron alpha et ribavirine : deux cas." La Revue de Médecine Interne 22, no. 12 (December 2001): 1248–52. http://dx.doi.org/10.1016/s0248-8663(01)00497-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Ngatcha, G., F. Rouibaa, S. Majdouli, A. Arouah, A. Feqhi, and A. Oubaaz. "Rétinopathie à interferon pégylé alpha 2a et ribavirine au cours d’une hépatite virale C chronique." Journal Africain d'Hépato-Gastroentérologie 7, no. 1 (December 8, 2012): 53–56. http://dx.doi.org/10.1007/s12157-012-0444-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Hocqueloux, M., C. Joyau, C. Aurelie, M. Hamidou, C. Agard, and A. Néel. "Traitement du VHC et Granulomatose sarcoïdose-like : 1 cas survenu sous Sofosbuvir+Ribavirine, sans interferon." La Revue de Médecine Interne 38 (December 2017): A135. http://dx.doi.org/10.1016/j.revmed.2017.10.060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Boudin, Laurys, Matthieu Patient, Precilla Tsitsi Nding Tsogou, Emilie Roméo, Jean-Sébastien Bladé, and Jean-Pierre de Jauréguiberry. "Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib." Bulletin du Cancer 106, no. 1 (January 2019): 84–85. http://dx.doi.org/10.1016/j.bulcan.2018.11.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Lunel-Fabiani, F., I. Fouchard-Hubert, and A. E. Gergely. "Traitement de l’anémie des patients atteints d’une hépatite C chronique sous interféron/ribavirine par l’érythropoïétine." Pathologie Biologie 51, no. 8-9 (October 2003): 520–24. http://dx.doi.org/10.1016/s0369-8114(03)00169-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Viennet, A., F. Glatre, and F. Bacin. "Rétinopathie à interferon alpha 2b et ribavirine chez un patient atteint d’une hépatite C chronique." Journal Français d'Ophtalmologie 32, no. 7 (September 2009): 505–10. http://dx.doi.org/10.1016/j.jfo.2009.04.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Seret, G., C. Pilette, L. Martin, S. Lanoiselée, F. Babinet, J. B. Pain, G. Peytavin, and A. Laradi. "Traitement d’une hépatite virale C chez un patient hémodialysé chronique par sofosbuvir et ribavirine : efficacité, sécurité et pharmacocinétique du sofsobuvir, du métabolite 007-TP dans le cadre d’une association sofosbuvir et de la ribavirine." Néphrologie & Thérapeutique 11, no. 5 (September 2015): 296. http://dx.doi.org/10.1016/j.nephro.2015.07.089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Calmus, Y., D. Samuel, G. Pageaux, M. Messner, P. Wolf, L. Rostaing, C. Vanlemmens, et al. "CO 24-Essai multicentrique national randomisé chez des malades ayant une récidive virale C post transplantation hépatique traités par peginterféron alfa-2a et ribavirine puis ribavirine seule : résultats à 18 mois de l’étude transpeg." Gastroentérologie Clinique et Biologique 30, no. 8-9 (August 2006): 1045. http://dx.doi.org/10.1016/s0399-8320(06)73403-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Hézode, C., D. Nelson, V. Rustgi, V. Balan, M. Sulkowski, J. McHutchison, G. Davis, et al. "CA 67-Réponse virologique prolongée à l’albumine interféron alfa-2b en combinaison avec la ribavirine chez des malades non répondeurs à un traitement préalable par interféron et ribavirine : résultats intermédiaires d’une étude de phase 2." Gastroentérologie Clinique et Biologique 30, no. 8-9 (August 2006): 1082. http://dx.doi.org/10.1016/s0399-8320(06)73477-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Cacoub, P., O. Lidove, P. Duhaut, N. Costedoat-Chalumeau, T. Maisonobe, V. Thibault, J. Servan, J. M. Léger, and J. C. Piette. "Interféron-alpha plus ribavirine chez les patients présentantune vascularite systémique associée au virus de l'hépatite C." La Revue de Médecine Interne 22 (December 2001): 473s. http://dx.doi.org/10.1016/s0248-8663(01)80114-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!